SNX-2112 is primarily investigated for its potential in cancer therapy, specifically as a selective inhibitor of heat shock protein 90 (Hsp90). Hsp90 plays a critical role in stabilizing various oncoproteins that drive tumor growth and survival. By inhibiting Hsp90, SNX-2112 promotes the degradation of these client proteins, leading to suppression of cancer cell proliferation and induction of apoptosis. It has shown preclinical activity against a range of cancers, including breast, lung, and prostate cancers, especially in tumors dependent on Hsp90-regulated signaling pathways such as HER2, AKT, and mutant BRAF. Due to its ability to simultaneously disrupt multiple oncogenic pathways, SNX-2112 is considered a promising candidate for overcoming resistance to single-target therapies. Research has also explored its use in combination with other anticancer agents to enhance therapeutic efficacy. While still largely in experimental stages, SNX-2112 contributes to the development of targeted cancer treatments with a broad mechanism of action.